Analysis of unplanned hospital readmissions up to 2-years after metastatic spine tumour surgery

Kumar, Naresh; Thomas, Allan; Madhu, Sirisha; Ramos, Miguel Rafael David; Shen, Liang; Tan, Joel Yong Hao; Villanueva, Andre; Ravikumar, Nivetha; Liu, Gabriel; Wong, Hee Kit

doi:10.1007/s00586-021-06723-5

Cited by 5 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28 (45.9%) of the MISS patients were treated for spinal instability alone and 33 (54.1%) were treated for MSCC, while in the OSS group, only 15 (10.8%) were treated for spinal instability alone and the rest 124 (89.2%) for MSCC (P < .001) (Table 1). The median SINS in our study was 13 (10)(11)(12)(13)(14)(15)(16)(17)(18).…”

Section: Demographic Datamentioning

confidence: 53%

“… 9 This is undesirable in MSD patients with limited life expectancies and multiple comorbidities. 10 , 11 In recent years, advancements in surgical techniques and technology have led to the advent of minimally invasive spine surgery (MISS). The aim of MISS is to achieve the same surgical goals as OSS, with the minimisation of approach-related morbidity.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Utility of ‘Minimal Access and Separation Surgery’ in the Management of Metastatic Spine Disease

Kumar

Tan

Thomas

et al. 2022

Global Spine Journal

Self Cite

View full text Add to dashboard Cite

Study Design Retrospective cohort study. Objectives To compare outcomes of percutaneous pedicle screw fixation (PPSF) to open posterior stabilization (OPS) in spinal instability patients and minimal access separation surgery (MASS) to open posterior stabilization and decompression (OPSD) in metastatic spinal cord compression (MSCC) patients. Methods We analysed patients who underwent surgery for thoracolumbar metastatic spine disease (MSD) from Jan 2011 to Oct 2017. Patients were divided into minimally invasive spine surgery (MISS) and open spine surgery (OSS) groups. Spinal instability patients were treated with PPSF/OPS with pedicle screws. MSCC patients were treated with MASS/OPSD. Outcomes measured included intraoperative blood loss, operative time, duration of hospital stay and ASIA-score improvement. Time to initiate radiotherapy and perioperative surgical/non-surgical complications was recorded. Propensity scoring adjustment analysis was utilised to address heterogenicity of histological tumour subtypes. Results Of 200 eligible patients, 61 underwent MISS and 139 underwent OSS for MSD. There was no significant difference in baseline characteristics between MISS and OSS groups. In the MISS group, 28 (45.9%) patients were treated for spinal instability and 33 (54.1%) patients were treated for MSCC. In the OSS group, 15 (10.8%) patients were treated for spinal instability alone and 124 (89.2%) were treated for MSCC. Patients who underwent PPSF had significantly lower blood loss (95 mL vs 564 mL; P < .001) and surgical complication rates( P < .05) with shorter length of stay approaching significance (6 vs 19 days; P = .100) when compared to the OPS group. Patients who underwent MASS had significantly lower blood loss (602 mL vs 1008 mL) and shorter length of stay (10 vs 18 days; P = .098) vs the OPSD group. Conclusion This study demonstrates the benefits of PPSF and MASS over OPS and OPSD for the treatment of MSD with spinal instability and MSCC, respectively.

show abstract

Section: Demographic Datamentioning

confidence: 53%

Section: Introductionmentioning

confidence: 99%

The Utility of ‘Minimal Access and Separation Surgery’ in the Management of Metastatic Spine Disease

Kumar

Tan

Thomas

et al. 2022

Global Spine Journal

Self Cite

View full text Add to dashboard Cite

show abstract

“…CC is a highly complex and heterogeneous tumor characterized by high morbidity and poor prognosis ( Kumar et al, 2021 ). Chemotherapy for CC has progressed in recent years, but tumor resistance is frequent when traditional histological and anatomical classifications are used to guide anti-tumor therapy.…”

Section: Discussionmentioning

confidence: 99%

Identification of RNA Methylation-Related lncRNAs Signature for Predicting Hot and Cold Tumors and Prognosis in Colon Cancer

Man

Huang

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

N6-methyladenosine (m6A), N1-methyladenosine (m1A), 5-methylcytosine (m5C), and 7-methylguanosine (m7G) are the major forms of RNA methylation modifications, which are closely associated with the development of many tumors. However, the prognostic value of RNA methylation-related long non-coding RNAs (lncRNAs) in colon cancer (CC) has not been defined. This study summarised 50 m6A/m1A/m5C/m7G-related genes and downloaded 41 normal and 471 CC tumor samples with RNA-seq data and clinicopathological information from The Cancer Genome Atlas (TCGA) database. A total of 1057 RNA methylation-related lncRNAs (RMlncRNAs) were identified with Pearson correlation analysis. Twenty-three RMlncRNAs with prognostic values were screened using univariate Cox regression analysis. By consensus clustering analysis, CC patients were classified into two molecular subtypes (Cluster 1 and Cluster 2) with different clinical outcomes and immune microenvironmental infiltration characteristics. Cluster 2 was considered to be the “hot tumor” with a better prognosis, while cluster 1 was regarded as the “cold tumor” with a poorer prognosis. Subsequently, we constructed a seven-lncRNA prognostic signature using the least absolute shrinkage and selection operator (LASSO) Cox regression. In combination with other clinical traits, we found that the RNA methylation-related lncRNA prognostic signature (called the “RMlnc-score”) was an independent prognostic factor for patients with colon cancer. In addition, immune infiltration, immunotherapy response analysis, and half-maximum inhibitory concentration (IC50) showed that the low RMlnc-score group was more sensitive to immunotherapy, while the high RMlnc-score group was sensitive to more chemotherapeutic agents. In summary, the RMlnc-score we developed could be used to predict the prognosis, immunotherapy response, and drug sensitivity of CC patients, guiding more accurate, and personalized treatment regimens.

show abstract

“…Colorectal cancer (CRC) has received a lot of attention and research due to its high incidence (10.2%) as well as high fatality rate (9.2%) among tumors worldwide ( 1 ). Because its early clinical symptoms are atypical and not obvious, CRC is often ignored, leading to delayed diagnosis and treatment.…”

Section: Introductionmentioning

confidence: 99%

Perspectives on Immunotherapy of Metastatic Colorectal Cancer

et al. 2021

View full text Add to dashboard Cite

Colorectal cancer, especially liver metastasis, is still a challenge worldwide. Traditional treatment such as surgery, chemotherapy and radiotherapy have been difficult to be further advanced. We need to develop new treatment methods to further improve the poor prognosis of these patients. The emergence of immunotherapy has brought light to mCRC patients, especially those with dMMR. Based on several large trials, some drugs (pembrolizumab, nivolumab) have been approved by US Food and Drug Administration to treat the patients diagnosed with dMMR tumors. However, immunotherapy has reached a bottleneck for other MSS tumors, with low response rate and poor PFS and OS. Therefore, more clinical trials are underway toward mCRC patients, especially those with MSS. This review is intended to summarize the existing clinical trials to illustrate the development of immunotherapy in mCRC patients, and to provide a new thinking for the direction and experimental design of immunotherapy in the future.

show abstract

Analysis of unplanned hospital readmissions up to 2-years after metastatic spine tumour surgery

Cited by 5 publications

References 27 publications

The Utility of ‘Minimal Access and Separation Surgery’ in the Management of Metastatic Spine Disease

The Utility of ‘Minimal Access and Separation Surgery’ in the Management of Metastatic Spine Disease

Identification of RNA Methylation-Related lncRNAs Signature for Predicting Hot and Cold Tumors and Prognosis in Colon Cancer

Perspectives on Immunotherapy of Metastatic Colorectal Cancer

Contact Info

Product

Resources

About